Unresectable Hepatocellular Carcinoma (HCC), BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
Conditions
Keywords
hepatocellular carcinoma, transarterial chemoembolization, hepatic arterial infusion chemotherapy, machine learning
Brief summary
The goal of this observational study is to learn about the efficacy of Transarterial Chemoembolization (TACE) versus Hepatic Arterial Infusion Chemotherapy (HAIC) in patients with unresectable hepatocellular carcinoma (HCC). The main questions it aims to answer are: Can distinct imaging phenotype subtypes be identified in unresectable HCC patients using radiomics and unsupervised clustering? Do these different imaging subtypes show significant differences in treatment efficacy (such as objective response rate, progression-free survival, and overall survival) after receiving TACE or HAIC? Can this method objectively identify which imaging subtype of patients is more suitable for TACE and which may benefit more from HAIC? Participants in this study are adult patients diagnosed with unresectable HCC (BCLC stage B or C) who have already undergone complete TACE or HAIC treatment as part of their regular medical care between January 2015 and December 2024. Researchers will retrospectively analyze their existing clinical data and pre-treatment medical images to compare outcomes.
Interventions
Sponsors
First Affiliated Hospital, Sun Yat-Sen University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Patients diagnosed with hepatocellular carcinoma (HCC) based on clinical or pathological criteria; 2. Barcelona Clinic Liver Cancer (BCLC) stage B or C, assessed as unresectable by surgical evaluation; 3. Received either TACE or HAIC as the sole interventional treatment modality throughout the treatment course (no crossover between the two modalities allowed); 4. Liver function classified as Child-Pugh Class A or B, or achieved this standard after medical treatment; 5. Performance status (PS) score of 0 or 1.
Exclusion criteria
1. Patients with an unclear diagnosis or those with concurrent other malignant tumors; 2. Liver function classified as Child-Pugh Class C or worse, which cannot be improved after hepatoprotective treatment; 3. Patients with severe infections, such as respiratory, biliary tract, or abdominal infections; 4. Patients with severe underlying diseases, particularly immune-related disorders. 5. Patients with severely incomplete or missing baseline or outcome data.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | From date of initial treatment until the date of death from any cause, whichever came first, assessed up to 24 months | Time interval from date of initial treatment until the date of death from any cause, whichever came first, assessed up to 24 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression free survival | From date of initial treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months | Time interval from date of initial treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months |
| Tumor response | From date of initial treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months | Defined as the proportion of patients achieving complete response (CR), partial response (PR), stable disease (SD) or progressive disease (PD) according to mRECIST criteria. |
Countries
China
Outcome results
None listed